Prothiaden (dosulepin)

Dosulepin (or PROTHIADEN®) is mainly prescribed to treat major depressive disorder.

Status: ACTIVE

Class: Tricyclic (TCA)

FDA Approval: International Only (Europe, Asia, Australia, New Zealand)

Dosage Forms: 25 mg, 75 mg

Biological Half-life: 14.4–23.9 hours

Side Effects: Dizziness, blurred vision, dry mouth, nausea, confusion, tachycardia, hypotension, arrhythmias, appetite changes, anxiety, urinary retention, extrapyramidal symptoms, increased suicide risk

Routes of Administration: Oral

Pregnancy Category: C (AU)